The Role of Measurable Residual Disease in AML

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

MRD in AML

Critical Questions for Assessing MRD in AML

Current Methods for Assessing MRD in AML

MRD Assessment in AML Is Not Yet Standardized

Is There a Preferred MRD Assay?

Standardization May Make MRD Assessment More Widely Available

Molecular Approaches to Assess MRD in AML

CyTOF to Measure MRD

Multiple Studies Demonstrate Prognostic Value of MRD in Younger Patients With AML

MRD Is an Independent Prognostic Factor

Molecular Monitoring of MRD in AML

Are 2 MRD Tests Better Than 1?

MRD Testing of Individual Genes vs Multigene Panels

What Is the Significance of Difficult-to-Clear Mutations?

Current State of MRD Testing in AML Expert Opinion

Effect of MRD on Transplant Outcomes

Using MRD in the Clinic Expert Guidance

Role of MRD Testing in Evaluating New AML Therapies

Converting MRD-Positive to MRD-Negative Can We Develop Therapies to Achieve This Goal?

Key Takeaways

Abbreviations

Abbreviations (cont)